格隆汇6月20日丨联邦制药(03933.HK)宣布, 于2025年6月20日,联邦生物已收取诺和诺德支付的预付款1.8亿美元(扣除丹麦预缴税后)。根据独家许可协议并受其条款和条件约束,联邦生物科技将有资格进一步收取最高18亿美元的潜在里程碑付款,视乎达成若干开发和销售里程碑而定,以及可收取基于该地区的年度净销售额计算的分层销售提成。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.